A Simple Key For BCAT-IN-4 Unveiled
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge a number of intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suf